Criterios para la fijación del valor de las acciones negociables en el mercado de capitales

El objetivo del trabajo fue, determinar los criterios para la fijación del valor de las acciones negociables en el mercado de capitales, a raíz de la aparición de nuevos factores de riesgo. Para ello, se caracterizo el mercado de capitales en Venezuela. Se determino los principales indicadores económicos y de mercado bursátil para la fijación del valor de las acciones. Se distinguió los factores de riesgo que engloban la fijación del valor de las acciones y las características del contexto político económico y social. Se consideraron los principios para la fijación del valor de las acciones tomando en cuenta el ambiente y los nuevos factores de riesgos. La metodología fue la hipotética deductiva no experimental transeccional descriptivo. El resultado concluye señalando la coexistencia de factores externos e internos del ambiente que intervienen en el desempeño de la actividad económica del país, causando variaciones que merman el patrimonio de las empresas originando disminución del precio del valor las acciones que se negocian en el mercado bursátil

Raman Spectroscopic Measurement of a Vacuum-Deposited C60 Thin Film

Measurement of Raman shifts of a C60 thin film and the evaluation of their uncertainties were conducted. A C60 thin film with a thickness of about 1.2 μm was fabricated on a SiO2 substrate by vacuum deposition. Raman spectra of the C60 thin film were obtained using the laser beam power density of 5.7 103 mW mm-2. The measured Raman shifts were corrected according to the calibration curve that was prepared using sulfur and naphthalene as the reference samples. Standard uncertainties were calculated and combined in order to determine the combined uncertainty and the expanded uncertainty. It was found that the increase of measurement time and measurement points for the calibration curve leads to the higher reliability

The P2X7 receptor contributes to seizures and inflammation-driven long-lasting brain hyperexcitability following hypoxia in neonatal mice.

Neonatal seizures represent a clinical emergency. However, current anti-seizure medications fail to resolve seizures in ~50% of infants. The P2X7 receptor (P2X7R) is an important driver of inflammation, and evidence suggests that P2X7R contributes to seizures and epilepsy in adults. However, no genetic proof has yet been provided to determine what contribution P2X7R makes to neonatal seizures, its effects on inflammatory signalling during neonatal seizures, and the therapeutic potential of P2X7R-based treatments on long-lasting brain excitability. Neonatal seizures were induced by global hypoxia in 7-day-old mouse pups (P7). The role of P2X7Rs during seizures was analysed in P2X7R-overexpressing and knockout mice. Treatment of wild-type mice after hypoxia with the P2X7R antagonist JNJ-47965567 was used to determine the effects of the P2X7R on long-lasting brain hyperexcitability. Cell type-specific P2X7R expression was analysed in P2X7R-EGFP reporter mice. RNA sequencing was used to monitor P2X7R-dependent hippocampal downstream signalling. P2X7R deletion reduced seizure severity, whereas P2X7R overexpression exacerbated seizure severity and reduced responsiveness to anti-seizure medication. P2X7R deficiency led to an anti-inflammatory phenotype in microglia, and treatment of mice with a P2X7R antagonist reduced long-lasting brain hyperexcitability. RNA sequencing identified several pathways altered in P2X7R knockout mice after neonatal hypoxia, including a down-regulation of genes implicated in inflammation and glutamatergic signalling. Treatments based on targeting the P2X7R may represent a novel therapeutic strategy for neonatal seizures with P2X7Rs contributing to the generation of neonatal seizures, driving inflammatory processes and long-term hyperexcitability states

Effective lagrangian for the tbH^+ interaction in the MSSM and charged Higgs phenomenology

In the framework of a 2HDM effective lagrangian for the MSSM, we analyse important phenomenological aspects associated with quantum soft SUSY-breaking effects that modify the relation between the bottom mass and the bottom Yukawa coupling. We derive a resummation of the dominant supersymmetric corrections for large values of \tb to all orders in perturbation theory. With the help of the operator product expansion we also perform the resummation of the leading and next-to-leading logarithms of the standard QCD corrections. We use these resummation procedures to compute the radiative corrections to the \tbH, \Htb decay rates. In the large \tb regime, we derive simple formulae embodying all the dominant contributions to these decay rates and we compute the corresponding branching ratios. We show, as an example, the effect of these new results on determining the region of the \mH--\tb plane excluded by the Tevatron searches for a supersymmetric charged Higgs boson in top quark decays, as a function of the MSSM parameter space.Comment: 33 pages, LaTeX, 17 figures, revised version submitted to Nuc. Phys.

Raman Spectroscopic Measurement of a Vacuum-Deposited C60 Thin Film

Measurement of Raman shifts of a C60 thin film and the evaluation of their uncertainties were conducted. A C60 thin film with a thickness of about 1.2 μm was fabricated on a SiO2 substrate by vacuum deposition. Raman spectra of the C60 thin film were obtained using the laser beam power density of 5.7 103 mW mm-2. The measured Raman shifts were corrected according to the calibration curve that was prepared using sulfur and naphthalene as the reference samples. Standard uncertainties were calculated and combined in order to determine the combined uncertainty and the expanded uncertainty. It was found that the increase of measurement time and measurement points for the calibration curve leads to the higher reliability

Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients

Contains fulltext : 177804.pdf (publisher's version ) (Open Access)BACKGROUND: Prostate cancer antigen 3 (PCA3) is a prostate cancer diagnostic biomarker that has been clinically validated. The limitations of the diagnostic role of PCA3 in initial biopsy and the prognostic role are not well established. Here, we elucidate the limitations of tissue PCA3 to predict high grade tumors in initial biopsy. RESULTS: PCA3 has a bimodal distribution in both biopsy and radical prostatectomy (RP) tissues, where low PCA3 expression was significantly associated with high grade disease (p/=8) with 55% sensitivity and high false negative rates; 42% of high Gleason (>/=8) samples had low PCA3. In RP, low PCA3 is associated with adverse pathological features, clinical recurrence outcome and greater probability of metastatic progression (p<0.001). MATERIALS AND METHODS: A total of 1,694 expression profiles from biopsy and 10,382 from RP patients with high risk tumors were obtained from the Decipher Genomic Resource Information Database (GRIDTM)prostate cancer database. The primary clinical endpoint was distant metastasis-free survival for RP and high Gleason grade for biopsy. Logistic regression analyses and Cox proportional hazards models were used to evaluate the association of PCA3 with clinical variables and risk of metastasis. CONCLUSIONS: There is high prevalence of high grade tumors with low PCA3 expression in the biopsy setting. Therefore, urologists should be warned that using PCA3 as stand-alone test may lead to high rate of under-diagnosis of high grade disease in initial biopsy setting

Observational constraint on generalized Chaplygin gas model

We investigate observational constraints on the generalized Chaplygin gas (GCG) model as the unification of dark matter and dark energy from the latest observational data: the Union SNe Ia data, the observational Hubble data, the SDSS baryon acoustic peak and the five-year WMAP shift parameter. It is obtained that the best fit values of the GCG model parameters with their confidence level are $A_{s}=0.73^{+0.06}_{-0.06}$ ($1\sigma$) $^{+0.09}_{-0.09}$ $(2\sigma)$, $\alpha=-0.09^{+0.15}_{-0.12}$ ($1\sigma$) $^{+0.26}_{-0.19}$ $(2\sigma)$. Furthermore in this model, we can see that the evolution of equation of state (EOS) for dark energy is similar to quiessence, and its current best-fit value is $w_{0de}=-0.96$ with the $1\sigma$ confidence level $-0.91\geq w_{0de}\geq-1.00$.Comment: 9 pages, 5 figure

Binding of myomesin to obscurin-like-1 to the muscle M-band provides a strategy for isoform-specific mechanical protection

The sarcomeric cytoskeleton is a network of modular proteins that integrate mechanical and signalling roles. Obscurin, or its homolog obscurin-like-1, bridges the giant ruler titin and the myosin crosslinker myomesin at the M-band. Yet, the molecular mechanisms underlying the physical obscurin(-like-1):myomesin connection, important for mechanical integrity of the M-band, remained elusive. Here, using a combination of structural, cellular, and single-molecule force spectroscopy techniques, we decode the architectural and functional determinants defining the obscurin(-like-1): myomesin complex. The crystal structure reveals a trans-complementation mechanism whereby an incomplete immunoglobulin-like domain assimilates an isoform-specific myomesin interdomain sequence. Crucially, this unconventional architecture provides mechanical stability up to forces of 135 pN. A cellular competition assay in neonatal rat cardiomyocytes validates the complex and provides the rationale for the isoform specificity of the interaction. Altogether, our results reveal a novel binding strategy in sarcomere assembly, which might have implications on muscle nanomechanics and overall M-band organization.We thank the Diamond Light Source and the European Synchrotron Radiation Laboratory for access to MX and SAXS beamlines, respectively. This work was supported by a British Heart Foundation grant (PG/10/67/28527) awarded to R.A.S. and M.G. as well as MRC grant MR/J010456/1 to M.G. and a British Heart Foundation grant (PG/13/50/30426) and EPSRC Fellowship (K00641X/1) to S.G.-M

Towards adaptive deep brain stimulation: clinical and technical notes on a novel commercial device for chronic brain sensing

Objective. Technical advances in deep brain stimulation (DBS) are crucial to improve therapeutic efficacy and battery life. We report the potentialities and pitfalls of one of the first commercially available devices capable of recording brain local field potentials (LFPs) from the implanted DBS leads, chronically and during stimulation. The aim was to provide clinicians with well-grounded tips on how to maximize the capabilities of this novel device, both in everyday practice and for research purposes. Approach. We collected clinical and neurophysiological data of the first 20 patients (14 with Parkinson's disease (PD), five with dystonia, one with chronic pain) that received the Percept (TM) PC in our centres. We also performed tests in a saline bath to validate the recordings quality. Main results. The Percept PC reliably recorded the LFP of the implanted site, wirelessly and in real time. We recorded the most promising clinically useful biomarkers for PD and dystonia (beta and theta oscillations) with and without stimulation. Furthermore, we provide an open-source code to facilitate export and analysis of data. Critical aspects of the system are presently related to contact selection, artefact detection, data loss, and synchronization with other devices. Significance. New technologies will soon allow closed-loop neuromodulation therapies, capable of adapting stimulation based on real-time symptom-specific and task-dependent input signals. However, technical aspects need to be considered to ensure reliable recordings. The critical use by a growing number of DBS experts will alert new users about the currently observed shortcomings and inform on how to overcome them.Scientific Assessment and Innovation in Neurosurgical Treatment Strategie